KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
about
Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.
P2860
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
KIR3DL2 (CD158k) is a potentia ...... naplastic large-cell lymphoma.
@en
type
label
KIR3DL2 (CD158k) is a potentia ...... naplastic large-cell lymphoma.
@en
prefLabel
KIR3DL2 (CD158k) is a potentia ...... naplastic large-cell lymphoma.
@en
P2093
P2860
P356
P1476
KIR3DL2 (CD158k) is a potentia ...... naplastic large-cell lymphoma.
@en
P2093
A Dujardin
C Bonnafous
C Ram-Wolff
F Jean-Louis
P2860
P304
P356
10.1111/BJD.14626
P407
P577
2016-04-01T00:00:00Z